SCHEMBL4899669

SCHEMBL4899669

Cc1cccc(-c2cc3ccccn3n2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.52
CCR8 P51685 1/20 0.52
GRM5 P41594 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
MAPK8 P45983 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK7 P50613 1/20 0.41
TYRO3 Q06418 1/20 0.41
LRRK2 Q5S007 1/20 0.41
AURKB Q96GD4 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
MIF P14174 1/20 0.40
PDE10A Q9Y233 1/20 0.40
METAP2 P50579 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237393 0.80 PDE10A (0.43) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL434570 0.75 MAP4K4 (0.54) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL11322916 0.75 KDM4E (0.50) CCR1CCR8GRM5MAP4K4ABL1
SCHEMBL31024090 0.75 KMT2A (0.53) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL13105299 0.74 NPC1 (0.52) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL5953401 0.73 HRH3 (0.51) MAP4K4ABL1MAPK8CSNK1A1CDK7
SCHEMBL31469917 0.72 IRAK4 (0.48) CDK7PIM2
SCHEMBL29388304 0.72 CCR1 (1.00) CCR1CCR8GRM5METAP2NPC1
SCHEMBL30511194 0.72 CCR1 (1.00) CCR1CCR8GRM5METAP2NPC1
SCHEMBL196966 0.72 CCR1 (1.00) CCR1CCR8GRM5METAP2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents BEIGHT DOUGLAS W 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents TGFB2, TGFB1, TGFBR1 CCR1 2671/4885CCR8 2258/4885GRM5 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.